Rundle Dana R, Rajala Raju V S, Anderson Robert E
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, U.S.A.
Exp Eye Res. 2002 Jul;75(1):87-97. doi: 10.1006/exer.2002.1189.
Protein myristoylation occurs when the 14 carbon fatty acid, myristic acid, is covalently attached by amide linkage to a protein's N -terminal glycine by an N -terminal myristoyltransferase (NMT). A variation of this called heterogeneous acylation occurs in vivo only in retina when specific proteins are modified by myristic acid (14:0), tetradecenoic acid (14:1 n-9), tetradecadienoic acid (14:2n -6), and lauric acid (12:0). Myristic and lauric acids are relatively rare, comprising approximately 1% of the fatty acids in the retina. The unsaturated fatty acids 14:1 n-9 and 14:2 n-6 are less abundant, but can be synthesized in retina by retroconversion of 18:1 n-9 and 18:2 n-6 fatty acids, respectively. A previous quantitative study of acyl-CoA pools in bovine retina, heart, and liver found comparable levels of acyl-CoAs in each tissue, indicating that heterogeneous acylation is not due to limiting amounts of myristoyl-CoA in retina. In this current study the authors have characterized a panel of purified recombinant Type I and II NMTs found in retina and liver by assessing their utilization of the four acyl-CoAs used in vivo to acylate retina proteins. Acceptor peptides used in these assays were derived from the N -termini of src which is only myristoylated in vivo, and the cAMP dependent kinase A catalytic subunit which is heterogeneously acylated in retina, but myristoylated in other tissues. The authors have tested the ability of unlabelled acyl-CoAs to compete with [(3)H] myristoyl-CoA transfer, the efficacy of an NMT inhibitory protein (NIP(71)), and acyl-CoA affinity chromatography was used to isolate endogenous NMT inhibitory factor(s) from bovine heart and retina tissue homogenates. These results provide a basis of kinetic parameters and enzymatic characterization for Type I and Type II NMTs with two acceptor peptides and the four physiologically relevant fatty acid-CoAs found on retinal proteins, but do not indicate that heterogeneous acylation is a specialized function of any of the enzymes tested in this study.
当14碳脂肪酸肉豆蔻酸通过N -末端肉豆蔻酰基转移酶(NMT)以酰胺键共价连接到蛋白质的N -末端甘氨酸上时,就会发生蛋白质肉豆蔻酰化。这种情况的一种变体称为异质酰化,仅在视网膜中发生于体内,此时特定蛋白质会被肉豆蔻酸(14:0)、十四碳烯酸(14:1 n-9)、十四碳二烯酸(14:2n -6)和月桂酸(12:0)修饰。肉豆蔻酸和月桂酸相对较少见,约占视网膜中脂肪酸的1%。不饱和脂肪酸14:1 n-9和14:2 n-6含量较少,但可分别通过18:1 n-9和18:2 n-6脂肪酸的逆向转化在视网膜中合成。先前一项对牛视网膜、心脏和肝脏中酰基辅酶A库的定量研究发现,每个组织中酰基辅酶A的水平相当,这表明异质酰化并非由于视网膜中肉豆蔻酰辅酶A的量有限。在本研究中,作者通过评估视网膜和肝脏中纯化的一组重组I型和II型NMT对体内用于酰化视网膜蛋白质的四种酰基辅酶A的利用情况,对其进行了表征。这些测定中使用的受体肽来自src的N -末端,src仅在体内被肉豆蔻酰化,以及cAMP依赖性蛋白激酶A催化亚基,其在视网膜中被异质酰化,但在其他组织中被肉豆蔻酰化。作者测试了未标记的酰基辅酶A与[(3)H]肉豆蔻酰辅酶A转移竞争的能力、一种NMT抑制蛋白(NIP(71))的功效,并使用酰基辅酶A亲和色谱法从牛心脏和视网膜组织匀浆中分离内源性NMT抑制因子。这些结果为具有两种受体肽和视网膜蛋白质上发现的四种生理相关脂肪酸 - 辅酶A的I型和II型NMT提供了动力学参数和酶学表征的基础,但并未表明异质酰化是本研究中测试的任何一种酶的特殊功能。